Humana (HUM) Q2 2026 Earnings Call Transcript

Humana reported 2Q26 adjusted EPS of $7.61, driven by Insurance segment operational performance and tighter G&A, but GAAP EPS of $5.73 was pressured by non-cash impairment and put/call valuation adjustments. For full-year guidance, adjusted EPS was affirmed at at least $9.00 while GAAP EPS guidance was cut to at least $6.52 (from $8.36) largely due to additional non-cash charges tied to the 2026 Star Ratings headwind for CMS quality bonuses. Management reaffirmed its path to a sustainable individual Medicare Advantage pretax margin of at least 3% by 2028, while highlighting 600,000 2027 MA plan exits and a $900M Gentiva divestiture plus $1.5B contingent pre-capitalized trust (P-Cap) liquidity to fund the MaxHealth acquisition and improve balance-sheet efficiency.

Analysis

The key market mechanism is not the headline earnings print; it is management signaling that growth is now subordinated to underwriting repair. That is usually a mixed read for insurers: it lowers the probability of a near-term margin cliff, but it also implies HUM is willing to cede share in lower-return MA books, which can cap revenue momentum and make the stock more sensitive to any miss on member retention. In the next 1-3 months, the setup is binary around October Stars and the December update: if either comes in merely "good enough" rather than clearly above peer cut points, the market will likely punish the absence of a clean inflection.

Second-order effects favor better-capitalized managed-care competitors and providers with stronger value-based care penetration. If HUM exits weaker plans and steers members toward higher-return geographies, competitors can pick up displaced lives, but only if they are willing to underwrite aggressively; that can pressure industry pricing discipline into 2027. The flip side is that HUM’s cost-centralization and care-delivery footprint make it one of the few payers with a credible path to compound margins even while shrinking low-quality revenue.

The main risk is that the current call may be underestimating how sticky pharmacy and specialty-drug inflation remains. Flat IBNR and prudent reserving reduce blow-up risk, but they do not remove earnings volatility if utilization normalizes upward or CMS cut points land unfavorably. Over 6-18 months, the real falsifier is a 2027 bid cycle that improves margin on paper but fails to preserve enough scale, leaving HUM smaller without a re-rate.

Key Decisions for Investors

• Short HUM on rallies into the Oct. Stars release and Dec. 10 update; use a 1-3 month horizon because the stock should stay headline-sensitive until the next visibility point. Risk/reward improves if shares rally on "progress" language without a verified Stars outcome.
• Buy HUM put spreads expiring after October Stars but before year-end if the stock trades up on the call; this targets disappointment risk with defined downside. Falsifier: a clearly favorable Stars result or an upside 2027 bid commentary that convinces the market the 2028 margin path is de-risked.
• Pair trade: long UNH / short HUM for relative-value exposure to MA execution risk and diversification. This works best if managed-care multiple dispersion widens on fears that HUM must sacrifice more volume to repair margins.
• Watch CMS as the cleaner read-through on policy risk; if MA reimbursement or Stars litigation headlines worsen, HUM should underperform first. If policy noise fades and HUM still lags, the issue is company-specific execution, not sector beta.